Does Baicapil block DHT? What the evidence shows

Hair loss driven by hormones affects a great many people, and beyond its visible effects it often weighs on confidence and wellbeing. This kind of hair loss is usually attributed to dihydrotestosterone, or DHT. Where DHT is overproduced, or where hair follicles are genetically sensitive to it, it is associated with a disrupted hair cycle: strands thin, weaken and eventually stop regrowing.

Many people turn to prescription medicines such as finasteride or dutasteride for this. These inhibit the enzyme 5α-reductase, which converts testosterone into DHT, and both have randomised trial evidence behind them in androgenetic alopecia. They also act systemically, and their labels list adverse effects that some people find intolerable, including sexual dysfunction and mood changes. That has driven interest in botanical products, among them Baicapil, a cosmetic ingredient marketed for hair growth. The question this article set out to answer is whether it blocks DHT without touching hormonal balance. The short answer, from the published evidence, is that no study has shown Baicapil blocks DHT at all. What follows is what the evidence does and does not show.

DHT: The silent saboteur behind thinning hair

Dihydrotestosterone is derived from testosterone through the action of the 5α-reductase enzyme. It contributes to male secondary sexual characteristics at puberty. In adults genetically predisposed to androgenetic alopecia (pattern hair loss), it is the hormone most strongly implicated in follicular miniaturisation — the process by which thick pigmented terminal hair is progressively replaced by finer, lighter hair until growth stops. The anagen (growth) phase shortens and the proportion of hairs in the telogen (shedding) phase rises, and over time affected areas of scalp visibly thin.

Finasteride reduces circulating DHT by inhibiting 5α-reductase. The US prescribing information for Propecia (finasteride 1 mg) lists adverse reactions reported by some users, including erectile dysfunction, decreased libido, ejaculation problems, gynecomastia, and depression. It also reports sexual side effects that continued after stopping, and depression and suicidal thoughts, from postmarketing reports; the label notes that these voluntary reports cannot show how often such effects happen or prove that the drug caused them. The UK regulator (MHRA, May 2026) states that finasteride is associated with depression, suicidal thoughts and sexual dysfunction "which may persist after treatment is stopped". These effects are why some people look for something else. Looking for something else is not the same as finding something that works, and the two should not be confused.

Baicapil: A natural strategy for hair revival

Baicapil is a cosmetic ingredient developed by the Provital Group. The manufacturer describes it as a topical botanical blend of three extracts: baicalin (from the root of Scutellaria baicalensis), young soybean sprouts (Glycine max), and wheat sprouts (Triticum vulgare). The company states these were chosen for their combined effect on hair growth and follicle vitality. Baicalin itself has been studied for anti-inflammatory and antioxidant activity, and separately in cancer cell biology.

Flavonoids such as baicalin are studied for their ability to neutralise oxidative stress and to influence cell signalling. Oxidative stress — an imbalance between free radicals and antioxidants — is one of the proposed contributors to hair follicle damage and ageing, though it is a hypothesis about hair loss rather than an established cause. Reducing it is proposed to make conditions more favourable for growth; that proposal has not been tested in a clinical trial of Baicapil.

Unlike medicines that act systemically, Baicapil is applied to the scalp. The manufacturer's proposed mechanism is that it acts on dermal papilla cells (specialised fibroblasts at the base of the follicle) and on follicular stem cell activity, which would prolong the anagen phase and slow miniaturisation. This is the company's stated hypothesis, not a demonstrated mechanism, and it is a different claim from blocking DHT.

What the manufacturer's own study reports

The most direct data on Baicapil comes from the Provital Group's own supplier documents — a non-peer-reviewed test in 61 volunteers, half of whom used a Baicapil lotion and half a placebo lotion, over 6 months. The supplier reports increased hair density and reduced hair fall.

Those figures cannot be independently checked. The test is not published in a peer-reviewed journal, and the year attributed to it differs between sources, so the specific percentages that circulate online are not reproduced here. The supplier describes a placebo lotion arm, but does not describe how people were allocated or whether assessors were blinded. The test was funded and run by the company selling the ingredient, and none of its results have been replicated by independent researchers. It should be read as manufacturer marketing data, not as clinical evidence.

Baicalin’s individual potential: More than just a plant extract

Baicalin has been studied on its own, though not for hair. The most directly relevant work is Chen and colleagues (Cell Proliferation, 2001), who tested baicalin and its metabolite baicalein on human prostate cancer cell lines — LNCaP, which is androgen-receptor positive, and JCA-1, which is not. Both compounds inhibited cell growth, and both reduced androgen receptor expression in LNCaP cells.

Two details in that paper matter more than the headline. First, the growth inhibition was stronger in the androgen-receptor-negative line, and the authors conclude that the effect "is independent of androgen receptor status" — so it is not an anti-androgen effect. Second, the concentrations involved were high (half-maximal growth inhibition at roughly 30–60 micromolar) and the compounds also drove cells into cell-cycle arrest and apoptosis; this is cancer cell biology, not a model of a hair follicle. A related paper, Bonham and colleagues (Clinical Cancer Research, 2005), characterised constituents of Scutellaria baicalensis with antiandrogenic and growth-inhibitory activity toward prostate carcinoma.

These are laboratory studies in cancer cell lines. Nothing in them shows that baicalin reduces DHT, blocks DHT at the follicle, or affects hair in a person, and translating them to the scalp would require animal work and then human trials that have not been done.

Does Baicapil block DHT without touching your hormonal balance?

On the published evidence, there is no basis for saying that Baicapil blocks DHT. No study has measured scalp or serum DHT in people using it, and the cell-line work on baicalin points away from an anti-androgen mechanism rather than toward one. The half of the question about hormonal balance is easier: a topically applied cosmetic ingredient is not expected to alter systemic hormones, and no evidence suggests it does — but "does not affect your hormones" is only reassuring alongside a treatment effect, and that has not been established either.

What can be said is narrower. Baicapil is a cosmetic ingredient with a plausible antioxidant rationale, one unpublished manufacturer study reporting benefit, and no independent, placebo-controlled, blinded trial. Independent randomised trials would be needed to confirm any effect and to describe long-term safety, and none has been published.

Anyone considering it should treat it as an unproven cosmetic rather than a substitute for a treatment with trial evidence. That distinction matters most for the readers this kind of product is marketed to: people who have had side effects on finasteride or dutasteride, or who would prefer a plant-derived option. Stopping a prescribed treatment in favour of a cosmetic is a decision to make with the prescriber, not on the strength of a manufacturer's dossier. The exception is a serious side effect: the UK regulator (MHRA, May 2026) advises stopping finasteride 1 mg immediately and contacting a doctor if depression or suicidal thoughts develop.

Baicapil is one of many botanical ingredients being explored for cosmetic and dermatological use. Its plant-based components, particularly baicalin, have laboratory activity that researchers have found interesting; that is a starting point for study rather than a reason to expect results on the scalp.

"Natural" does not mean effective, and it does not mean safe. Talk to a doctor, dermatologist or pharmacist before starting any new hair treatment, before adding a product to an existing regimen, and — most importantly — before stopping or replacing a prescribed medication.

References and research sources

Chen, S., Ruan, Q., Bedner, E., Deptala, A., Wang, X., Hsieh, T. C., Traganos, F., & Darzynkiewicz, Z. (2001). Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines. Cell Proliferation, 34(5), 293–304. https://pubmed.ncbi.nlm.nih.gov/11591177/

Bonham, M., Posakony, J., Coleman, I., Montgomery, B., Simon, J., & Nelson, P. S. (2005). Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma. Clinical Cancer Research, 11(10), 3905–3914. https://pubmed.ncbi.nlm.nih.gov/15897592/

Organon. Propecia (finasteride) tablets, US prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f904709-65aa-44ce-b144-b4c8a0416e36

Medicines and Healthcare products Regulatory Agency. (2026, May 11). Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction. Drug Safety Update. https://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction

Provital. (2013). Baicapil hair growth leaflet (supplier document V01-2013). Manufacturer's own unpublished data; not peer-reviewed. https://biotechnologia.pl/uploads/biotechnologia/product/leaflet/675879/Baicapil_hairgrowth_eng.pdf